Puma Biotechnology (NASDAQ:PBYI) Lowered to “Hold” Rating by Wall Street Zen

Puma Biotechnology (NASDAQ:PBYI) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Puma Biotechnology in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Puma Biotechnology Stock Performance

NASDAQ PBYI opened at $5.70 on Friday. The stock has a market cap of $287.22 million, a price-to-earnings ratio of 9.34 and a beta of 1.22. The business has a 50 day simple moving average of $6.50 and a 200 day simple moving average of $5.59. Puma Biotechnology has a 52-week low of $2.58 and a 52-week high of $7.68.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.02. Puma Biotechnology had a net margin of 13.62% and a return on equity of 29.42%. The company had revenue of $75.50 million during the quarter, compared to analysts’ expectations of $68.60 million. On average, analysts predict that Puma Biotechnology will post 0.31 EPS for the current year.

Insider Buying and Selling at Puma Biotechnology

In other Puma Biotechnology news, insider Douglas M. Hunt sold 5,014 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total transaction of $29,482.32. Following the sale, the insider directly owned 155,907 shares of the company’s stock, valued at $916,733.16. The trade was a 3.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Alan H. Auerbach sold 18,012 shares of the stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $5.88, for a total transaction of $105,910.56. Following the transaction, the chief executive officer owned 7,145,951 shares of the company’s stock, valued at approximately $42,018,191.88. This represents a 0.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 43,937 shares of company stock valued at $257,513 in the last 90 days. 23.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PBYI. Acorn Capital Advisors LLC raised its stake in shares of Puma Biotechnology by 4.9% during the 2nd quarter. Acorn Capital Advisors LLC now owns 4,131,299 shares of the biopharmaceutical company’s stock worth $14,170,000 after purchasing an additional 191,247 shares in the last quarter. American Century Companies Inc. increased its holdings in Puma Biotechnology by 16.8% during the second quarter. American Century Companies Inc. now owns 1,342,275 shares of the biopharmaceutical company’s stock worth $4,604,000 after buying an additional 192,615 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Puma Biotechnology by 5.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,339,603 shares of the biopharmaceutical company’s stock worth $7,971,000 after acquiring an additional 67,725 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its stake in Puma Biotechnology by 35.3% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock valued at $6,666,000 after acquiring an additional 292,108 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in Puma Biotechnology by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 994,345 shares of the biopharmaceutical company’s stock valued at $5,917,000 after acquiring an additional 10,823 shares during the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Trending Headlines about Puma Biotechnology

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Q4 results beat consensus — revenue grew roughly 28% (about $75.5M) and EPS topped estimates, showing operational momentum heading into 2026. Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Company expects NERLYNX revenue of $194M–$198M for 2026 and continues to advance its alisertib clinical programs — signals of product revenue stability and pipeline progress. Puma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical
• Neutral Sentiment: Management held an earnings call and published the transcript/slide deck — useful for investors wanting detail on assumptions behind guidance and commercialization plans. Puma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic …
• Negative Sentiment: Forward guidance disappointed — Q1 2026 revenue guidance of $38M–$42M and FY‑2026 revenue of $214M–$221M came in below consensus, raising concerns about near‑term top‑line growth versus Street expectations. PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
• Negative Sentiment: Market reaction amplified the move — shares fell sharply in after‑hours trading on the weak outlook and liquidity pushed volume well above average, increasing downside pressure. Puma Biotechnology (PBYI) announced its earnings results on Thursday.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.